Peptides conjugated to gold nanoparticles induce macrophage activation

Molecular Immunology

Volumn 46, Issue 4, 2009, Pages 743-748

  Bastús, Neus G ^a,b   Sánchez Tilló, Ester ^c   Pujals, Silvia ^c   Farrera, Consol ^c   Kogan, Marcelo J ^c,d   Giralt, Ernest ^b,c   Celada, Antonio ^c   Lloberas, Jorge ^c   Puntes, Victor ^a,e  

^a CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d UNIVERSITY OF CHILE   (Chile)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Adjuvants; Macrophage; Nanoparticles; Toll like receptor

Indexed keywords

AMYLOID GROWTH INHIBITORY PEPTIDE; CYTOKINE; GOLD; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NANOPARTICLE; NITRIC OXIDE SYNTHASE; PEPTIDE; SWEET ARROW PEPTIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL POLARITY; CELL PROLIFERATION; EXPERIMENTAL STUDY; MACROPHAGE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL PROLIFERATION; GOLD; MACROPHAGE ACTIVATION; MACROPHAGES; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDES; TOLL-LIKE RECEPTOR 4;

EID: 58249094974     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.08.277     Document Type: Article

References (30)

1. Alderson M.R., McGowan P., Baldridge J.R., and Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12 (2006) 313-319
2. Blondiau C., Lagadec P., Lejeune P., Onier N., Cavaillon J.M., and Jeannin J.F. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiology 190 (1994) 243-254
3. Celada A., Gray P.W., Rinderknecht E., and Schreiber R.D. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J. Exp. Med. 160 (1984) 55-74
4. Celada A., and Maki R.A. Transforming growth factor-beta enhances the M-CSF and GM-CSF-stimulated proliferation of macrophages. J. Immunol. 148 (1992) 1102-1105
5. Conner S.D., and Schmid S.L. Regulated portals of entry into the cell. Nature 422 (2003) 37-44
6. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., Li H., Coffman R., Seyfert V., Eiden J.J., and Broide D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355 (2006) 1445-1455
7. Fernandez-Carneado J., Kogan M.J., Castel S., and Giralt E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew. Chem. Int. Ed. Engl. 43 (2004) 1811-1814
8. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162 (1999) 3749-3752
9. Johnson D.A. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr. Top. Med. Chem. 8 (2008) 64-79
10. Kandimalla E.R., Zhu F.G., Bhagat L., Yu D., and Agrawal S. Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem. Soc. Trans. 31 (2003) 654-658
11. Kimling J., Maier M., Okenve B., Kotaidis V., Ballot H., and Plech A. Turkevich method for gold nanoparticle synthesis revisited. J. Phys. Chem. B 110 (2006) 15700-15707
12. Kogan M.J., Bastus N.G., Amigo R., Grillo-Bosch D., Araya E., Turiel A., Labarta A., Giralt E., and Puntes V.F. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 6 (2006) 110-115
13. Krieg A.M., and Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3 (2001) 15-24
14. Lucarelli M., Gatti A.M., Savarino G., Quattroni P., Martinelli L., Monari E., and Boraschi D. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur. Cytokine Netw. 15 (2004) 339-346
15. Marques L., Brucet M., Lloberas J., and Celada A. STAT1 regulates lipopolysaccharide- and TNF-alpha-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J. Immunol. 173 (2004) 1103-1110
16. McKee A.S., Munks M.W., and Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27 (2007) 687-690
17. Morefield G.L., Hawkins L.D., Ishizaka S.T., Kissner T.L., and Ulrich R.G. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14 (2007) 1499-1504
18. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., Chow J.C., and Strauss III J.F. The extra domain A of fibronectin activates toll-like receptor 4. J. Biol. Chem. 276 (2001) 10229-10233
19. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., Sohn J.W., Yamada S., Maruyama I., Banerjee A., Ishizaka A., and Abraham E. High mobility group box 1 protein interacts with multiple toll-like receptors. Am. J. Physiol. Cell Physiol. 290 (2006) C917-C924
20. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11 (2005) S63-S68
21. Peek L.J., Middaugh C.R., and Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 (2008) 915-928
22. Portney N.G., and Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal. Bioanal. Chem. 384 (2006) 620-630
23. Rabinovich N.R., McInnes P., Klein D.L., and Hall B.F. Vaccine technologies: view to the future. Science 265 (1994) 1401-1404
24. Ryan J.J., Bateman H.R., Stover A., Gomez G., Norton S.K., Zhao W., Schwartz L.B., Lenk R., and Kepley C.L. Fullerene nanomaterials inhibit the allergic response. J. Immunol. 179 (2007) 665-672
25. Sanchez-Tillo E., Comalada M., Xaus J., Farrera C., Valledor A.F., Caelles C., Lloberas J., and Celada A. JNK1 is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation. J. Biol. Chem. 282 (2007) 12566-12573
26. Turvey S.E., and Hawn T.R. Towards subtlety: understanding the role of toll-like receptor signaling in susceptibility to human infections. Clin. Immunol. 120 (2006) 1-9
27. Uhlmann E., and Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Develop. 6 (2003) 204-217
28. Valledor A.F., Sanchez-Tillo E., Arpa L., Park J.M., Caelles C., Lloberas J., and Celada A. Selective roles of MAPKs during the macrophage response to IFN-{gamma}. J. Immunol. 180 (2008) 4523-4529
29. Warren J.R. Polymyxin B suppresses the endotoxin inhibition of concanavalin a-mediated erythrocyte agglutination. Infect. Immun. 35 (1982) 594-599
30. Xaus J., Cardo M., Valledor A.F., Soler C., Lloberas J., and Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 11 (1999) 103-113